Analysts Set Certara, Inc. (NASDAQ:CERT) PT at $13.82

Certara, Inc. (NASDAQ:CERT) has been assigned a consensus rating of “Moderate Buy” from the fifteen research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have given a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $13.8182.

Several analysts recently commented on CERT shares. UBS Group cut their target price on shares of Certara from $17.50 to $15.00 and set a “buy” rating for the company in a research note on Thursday, August 7th. Rothschild Redb upgraded Certara to a “strong-buy” rating in a research report on Friday, November 21st. Barclays reduced their price objective on Certara from $16.00 to $14.00 and set an “overweight” rating for the company in a research note on Friday, November 7th. Rothschild & Co Redburn began coverage on Certara in a research report on Friday, November 21st. They set a “buy” rating and a $10.00 target price on the stock. Finally, Zacks Research raised Certara from a “strong sell” rating to a “hold” rating in a report on Friday, September 5th.

Certara Trading Up 4.4%

Shares of CERT stock opened at $9.68 on Friday. The stock has a 50-day simple moving average of $10.92 and a 200 day simple moving average of $10.98. The stock has a market capitalization of $1.54 billion, a P/E ratio of 138.29 and a beta of 1.46. Certara has a fifty-two week low of $8.02 and a fifty-two week high of $15.69. The company has a quick ratio of 2.09, a current ratio of 2.09 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.11 by $0.03. Certara had a net margin of 2.62% and a return on equity of 5.18%. The firm had revenue of $104.62 million for the quarter, compared to analysts’ expectations of $104.53 million. During the same period in the previous year, the business earned $0.13 earnings per share. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. On average, sell-side analysts expect that Certara will post 0.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the company’s stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $10.92, for a total transaction of $559,366.08. Following the completion of the sale, the insider directly owned 73,979 shares of the company’s stock, valued at approximately $807,850.68. This represents a 40.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 2.33% of the company’s stock.

Institutional Investors Weigh In On Certara

Large investors have recently made changes to their positions in the company. Private Advisor Group LLC boosted its stake in Certara by 4.0% in the 1st quarter. Private Advisor Group LLC now owns 24,517 shares of the company’s stock worth $243,000 after purchasing an additional 949 shares during the period. KLP Kapitalforvaltning AS lifted its holdings in shares of Certara by 21.2% in the first quarter. KLP Kapitalforvaltning AS now owns 31,400 shares of the company’s stock valued at $311,000 after purchasing an additional 5,500 shares in the last quarter. Avantax Advisory Services Inc. boosted its position in shares of Certara by 53.0% in the first quarter. Avantax Advisory Services Inc. now owns 51,788 shares of the company’s stock worth $513,000 after buying an additional 17,931 shares during the period. Pacer Advisors Inc. acquired a new stake in shares of Certara in the first quarter worth $144,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Certara by 29.7% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 40,721 shares of the company’s stock valued at $403,000 after buying an additional 9,330 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.